Literature DB >> 12427779

Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

M van Rijnsoever1, F Grieu, H Elsaleh, D Joseph, B Iacopetta.   

Abstract

BACKGROUND AND AIMS: A subgroup of colorectal cancers (CRC) referred to as the CpG island methylator phenotype (CIMP+) shows simultaneous methylation of multiple CpG islands. The clinicopathological and molecular characteristics of this phenotype remain uncertain however.
METHODS: We analysed methylation of CpG islands in the p16 and MDR1 genes and MINT-2 clone in 275 stage II/III CRCs.
RESULTS: Concurrent methylation of two or more CpG islands was observed in 32% of cases and was considered to represent CIMP+. These were often poorly differentiated, had less TP53 mutations, and originated frequently in the proximal or higher stage CRC compared with CIMP- tumours (p<0.05 for each). CIMP+ had no prognostic significance in stage II or stage III CRC treated by surgery alone. hMLH1 methylated tumours comprised the majority (81%) of cases with microsatellite instability, were frequently observed in older female patients, were often poorly differentiated or CIMP+, and contained wild-type K-ras (p<0.05 for each). Females who were heterozygous or homozygous for the C677T MTHFR polymorphism were at increased risk of developing CIMP+ CRC (odds ratio 2.17, 95% confidence interval 1.03-4.57; p=0.037).
CONCLUSIONS: These observations made in a relatively large unselected series of CRC support the notion that CIMP+ characterises a subgroup of tumours with distinctive phenotypic features.

Entities:  

Mesh:

Year:  2002        PMID: 12427779      PMCID: PMC1773491          DOI: 10.1136/gut.51.6.797

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Promoter methylation analysis on microdissected paraffin-embedded tissues using bisulfite treatment and PCR-SSCP.

Authors:  Y S Bian; P Yan; M C Osterheld; C Fontolliet; J Benhattar
Journal:  Biotechniques       Date:  2001-01       Impact factor: 1.993

2.  Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women.

Authors:  S R Malkhosyan; H Yamamoto; Z Piao; M Perucho
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.

Authors:  H Elsaleh; B Powell; K McCaul; F Grieu; R Grant; D Joseph; B Iacopetta
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

4.  Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features.

Authors:  B A Shannon; B J Iacopetta
Journal:  Cancer Lett       Date:  2001-06-10       Impact factor: 8.679

5.  MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.

Authors:  Y Tada; M Wada; K Kuroiwa; N Kinugawa; T Harada; J Nagayama; M Nakagawa; S Naito; M Kuwano
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

6.  Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer.

Authors:  N Burri; P Shaw; H Bouzourene; I Sordat; B Sordat; M Gillet; D Schorderet; F T Bosman; P Chaubert
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

7.  Dietary intake and microsatellite instability in colon tumors.

Authors:  M L Slattery; K Anderson; K Curtin; K N Ma; D Schaffer; W Samowitz
Journal:  Int J Cancer       Date:  2001-08-15       Impact factor: 7.396

8.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer.

Authors:  M Esteller; S González; R A Risques; E Marcuello; R Mangues; J R Germà; J G Herman; G Capellà; M A Peinado
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

9.  Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer.

Authors:  M L Slattery; J D Potter; K Curtin; S Edwards; K N Ma; K Anderson; D Schaffer; W S Samowitz
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

10.  Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.

Authors:  R Soong; B Powell; H Elsaleh; G Gnanasampanthan; D R Smith; H S Goh; D Joseph; B Iacopetta
Journal:  Eur J Cancer       Date:  2000-10       Impact factor: 9.162

View more
  86 in total

Review 1.  Aberrant DNA methylation: have we entered the era of more than one type of colorectal cancer?

Authors:  Barry Iacopetta
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.

Authors:  Noriko Tanaka; Curtis Huttenhower; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; John Quackenbush; Kevin M Haigis; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 3.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

4.  Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.

Authors:  Jeong Mo Bae; Mi Jung Kim; Jung Ho Kim; Jae Moon Koh; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

5.  5,10-methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer.

Authors:  Allison M Eaton; Robert Sandler; John M Carethers; Robert C Millikan; Joseph Galanko; Temitope O Keku
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-08       Impact factor: 4.254

6.  Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.

Authors:  Yutaka Suehiro; Chi Wai Wong; Lucian R Chirieac; Yutaka Kondo; Lanlan Shen; C Renee Webb; Yee Wai Chan; Annie S Y Chan; Tsun Leung Chan; Tsung-Teh Wu; Asif Rashid; Yuichiro Hamanaka; Yuji Hinoda; Rhonda L Shannon; Xuemei Wang; Jeffrey Morris; Jean-Pierre J Issa; Siu Tsan Yuen; Suet Yi Leung; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

7.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

8.  Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity.

Authors:  Hiroyuki Mitomi; Naoshi Fukui; Nobuho Tanaka; Hideki Kanazawa; Tsuyoshi Saito; Takashi Matsuoka; Takashi Yao
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

9.  Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.

Authors:  Patrick Chun; Zev A Wainberg
Journal:  Gastrointest Cancer Res       Date:  2009-09

10.  Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability.

Authors:  Luciano Delgado-Plasencia; Vicente Medina-Arana; Alberto Bravo-Gutiérrez; Julián Pérez-Palma; Hugo Álvarez-Argüelles; Eduardo Salido-Ruiz; Antonia M Fernández-Peralta; Juan J González-Aguilera
Journal:  Int J Colorectal Dis       Date:  2013-02-20       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.